TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18248661

Group type: EXPERIMENTAL
Intervention: Intraduodenal PHA (150 microg, 1.5 mg, 15 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Heat-inactivated PHA
Number of subjects: 5

Group type: COMPARATOR
Intervention: CCK(1) receptor antagonist dexloxiglumide
Number of subjects: 5

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 5
Study: 16203879

Group type: EXPERIMENTAL
Intervention: Ximelagatran (36 mg twice daily)
Number of subjects: 1949

Group type: COMPARATOR
Intervention: Warfarin (target INR 2.5)
Number of subjects: 1949
Study: 11902626

Group type: EXPERIMENTAL
Intervention: Priming environmental values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced self-focus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Value-activation and centrality measures
Number of subjects: 0
Study: 10201726

Group type: EXPERIMENTAL
Intervention: Planet Health intervention
Number of subjects: 1295
Study: 7844607

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy with cisplatin 60 mg/m2 and epirubicin 110 mg/m2 administered at 3-week intervals for three cycles, followed by pelvic radiotherapy.
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard pelvic radiotherapy alone.
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Combined modality treatment (chemotherapy followed by radiotherapy).
Number of subjects: 260
Study: 2333832

Group type: EXPERIMENTAL
Intervention: 100 mg oral caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg oral caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg oral caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 313353

Group type: COMPARATOR
Intervention: Intravenous vasopressin (IVV) started at 0.3 U/min, increased to 1.5 U/min as needed
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intraarterial vasopressin (IAV) started at 0.1 U/min, increased to 0.5 U/min as needed
Number of subjects: 22
Study: 31640486

Group type: EXPERIMENTAL
Intervention: Mobility salience condition (completed a mobility perception scale)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Neutral scale condition (control group)
Number of subjects: 215
Study: 31319060

Group type: EXPERIMENTAL
Intervention: AmplifEYE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocuff Vision
Number of subjects: 0
Study: 28397083

Group type: EXPERIMENTAL
Intervention: H‐RME on second deciduous molars (GrE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: H‐RME on first permanent molars (Gr6)
Number of subjects: 70
Study: 25664323

Group type: EXPERIMENTAL
Intervention: AndoSan (mushroom extract containing 82% Agaricus blazei Murrill)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25415862

Group type: EXPERIMENTAL
Intervention: Training course for screening obstetric ultrasound (10-day course with quality assurance activities)
Number of subjects: 0
Study: 23032746

Group type: EXPERIMENTAL
Intervention: Vismodegib (GDC‐0449; 150 mg daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 104
Study: 19676125

Group type: EXPERIMENTAL
Intervention: 360 microg PEG‐IFNalpha‐2a weekly plus ribavirin at 1000‐1200 mg/day for 12 weeks
Number of subjects: 896

Group type: COMPARATOR
Intervention: 180 microg PEG‐IFNalpha‐2a weekly plus ribavirin at 1000‐1200 mg/day for 12 weeks
Number of subjects: 896
Study: 17166775

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) adjunctive treatment
Number of subjects: 158
Study: 15850856

Group type: EXPERIMENTAL
Intervention: Brief counseling and print materials
Number of subjects: 450

Group type: COMPARATOR
Intervention: Print materials alone
Number of subjects: 450
Study: 12072599

Group type: EXPERIMENTAL
Intervention: Omeprazole MUPS 20 mg
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 461
Study: 9594927

Group type: EXPERIMENTAL
Intervention: Lipid altering or antioxidant vitamins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8934728

Group type: EXPERIMENTAL
Intervention: FEC with high-dose infusional 5-fluorouracil (750 mg/m2 per day/days 1 to 5)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard FEC regimen (5‐FU 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: FEC with high-dose infusional 5-fluorouracil
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard FEC regimen
Number of subjects: 178
Study: 2235919

Group type: EXPERIMENTAL
Intervention: Fecal occult blood test performance after initial test mailing and follow-up mailing.
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing among past nontesters (n = 121).
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing among past testers (n = 201).
Number of subjects: 504
Study: 233444

Group type: EXPERIMENTAL
Intervention: tiapride 300 mg/day
Number of subjects: 30
Study: 30157242

Group type: EXPERIMENTAL
Intervention: subtype C prophylactic vaccine (DNA prime: ADVAX and MVA boost: TBC-M4)
Number of subjects: 0
Study: 26498057

Group type: EXPERIMENTAL
Intervention: Testosterone solution 2% (60 mg topical, once daily)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Testosterone solution 2%
Number of subjects: 715
Study: 24353345

Group type: EXPERIMENTAL
Intervention: Higher erythrocyte membrane eicosapentaenoic acid proportions
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Higher current fish consumption
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Greater fish consumption in childhood
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Higher proportions of long-chain n-3 fatty acids or fish intake
Number of subjects: 390
Study: 23427383

Group type: EXPERIMENTAL
Intervention: Liandouqingmai Recipe
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 101
Study: 20409627

Group type: EXPERIMENTAL
Intervention: Microsim e-learning programme
Number of subjects: 572

Group type: COMPARATOR
Intervention: Control group (course manual and pre-course MCQ)
Number of subjects: 572
Study: 18712644

Group type: EXPERIMENTAL
Intervention: Combined electroacupuncture and strength training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Strength training alone
Number of subjects: 10
Study: 15992754

Group type: EXPERIMENTAL
Intervention: 1CU accommodative IOL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acrysof MA30 monofocal IOL
Number of subjects: 30
Study: 12088970

Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl (12 mg of hyperbaric bupivacaine plus 12.5 microg of fentanyl)
Number of subjects: 48

Group type: COMPARATOR
Intervention: IV Fentanyl (12.5 microg administered immediately after spinal anesthesia)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl
Number of subjects: 48

Group type: COMPARATOR
Intervention: IV Fentanyl
Number of subjects: 48
Study: 10893091

Group type: EXPERIMENTAL
Intervention: NCPAP set at therapeutic levels of pressure
Number of subjects: 101

Group type: COMPARATOR
Intervention: NCPAP set at sub‐therapeutic pressure levels
Number of subjects: 101
Study: 8968156

Group type: EXPERIMENTAL
Intervention: RT‐23 (2 TU PPD)
Number of subjects: 98

Group type: COMPARATOR
Intervention: 5 TU PPD
Number of subjects: 98
Study: 1844926

Group type: EXPERIMENTAL
Intervention: Intermittent bolus feeding via nasogastric tube (Group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Continuous drip feeding via nasogastric tube (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ad-libitum feeding by oral route (Group C)
Number of subjects: 42
Study: 6499512

Group type: EXPERIMENTAL
Intervention: 500 mg spiramycin 3-times daily for 3 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: 500 mg erythromycin 3-times daily for 5 days
Number of subjects: 64
Study: 28965157

Group type: EXPERIMENTAL
Intervention: Listening to Holy Quran recitation (HQR) for 30 minutes
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group with 30 minutes of rest in bed
Number of subjects: 55
Study: 30291997

Group type: EXPERIMENTAL
Intervention: 30-day CHW intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care (no CHW)
Number of subjects: 1200
Study: 26853792

Group type: EXPERIMENTAL
Intervention: lidocaine gel+lidocaine spray
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: base lubricant gel+lidocaine spray
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: lidocaine gel+isotonic spray
Number of subjects: 180
Study: 25759182

Group type: EXPERIMENTAL
Intervention: Web-based decision support program
Number of subjects: 113
Study: 22429264

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with reverse remodeling
Number of subjects: 119

Group type: COMPARATOR
Intervention: Non-responders to CRT
Number of subjects: 119
Study: 20230067

Group type: EXPERIMENTAL
Intervention: Goal-setting program
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control task with intervention-quality face validity
Number of subjects: 85
Study: 18373315

Group type: EXPERIMENTAL
Intervention: CVVHDF (pre-dilution volume of 600 mls/h with a dialysate dose of 1 L)
Number of subjects: 45

Group type: COMPARATOR
Intervention: CVVH (ultrafiltrate dose of 35 ml/kg/h)
Number of subjects: 45
Study: 16035676

Group type: EXPERIMENTAL
Intervention: Silicone cushion (Clinicel)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Silicone occlusive sheeting
Number of subjects: 72
Study: 11932655

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage (CSFD) initiated during the operation and continued for 48 hours after surgery, target CSF pressure 10 mm Hg or less
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no CSFD)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage (CSFD)
Number of subjects: 145
Study: 10086723

Group type: EXPERIMENTAL
Intervention: High-dose asparaginase consolidation (25,000 IU/m2) given weekly for 20 weeks by intramuscular injection
Number of subjects: 552

Group type: COMPARATOR
Intervention: Control regimen (no high-dose asparaginase)
Number of subjects: 552
Study: 7724752

Group type: EXPERIMENTAL
Intervention: Contrast material concentration of 240 mg of iodine per milliliter
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Contrast material volume
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Contrast material concentration
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Calculated iodine dose based on patient weight
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Contrast material concentration of 240 mg I/mL
Number of subjects: 200
Study: 2081010

Group type: EXPERIMENTAL
Intervention: Increased dietary sodium intake
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Change in serum 1,25-dihydroxyvitamin D
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Change in plasma renin activity
Number of subjects: 10
Study: 6356317

Group type: EXPERIMENTAL
Intervention: Sucralfate (2 tablets of 500 mg 4 times daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 31062349

Group type: EXPERIMENTAL
Intervention: AVP-825 (22 mg)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Oral Sumatriptan (100 mg)
Number of subjects: 259
Study: 30389036

Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 258

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 258
Study: 26497508

Group type: EXPERIMENTAL
Intervention: Psychosocial stress (Trier Social Stress Test, TSST)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control session (no stress)
Number of subjects: 85
Study: 24570986

Group type: EXPERIMENTAL
Intervention: Conventional SRP and diode laser (GaAlAs)‐assisted pocket debridement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional SRP
Number of subjects: 30
Study: 21339698

Group type: EXPERIMENTAL
Intervention: Whole-body vibration with alternative tilting (WBVAT)
Number of subjects: 53
Study: 19462277

Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline-treated control group (placebo)
Number of subjects: 30
Study: 21545948

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2908

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2908
Study: 16418554

Group type: EXPERIMENTAL
Intervention: Delivery nursing care using essential oils
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 11826205

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (0.5 mg/kg/d for 3 days)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (0.2 mg/kg/d for 3 days and 0.1 mg/kg/d for 4 days)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both high-dose and low-dose dexamethasone
Number of subjects: 47
Study: 10811522

Group type: EXPERIMENTAL
Intervention: Daflon (flavonoids)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8526459

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1441
Study: 2391398

Group type: EXPERIMENTAL
Intervention: flurbiprofen 200 mg plus ranitidine 150 mg bid for 7 days before and for 2 days after receiving flurbiprofen
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: flurbiprofen 200 mg plus cimetidine 300 mg qid for 7 days before and for 2 days after receiving flurbiprofen
Number of subjects: 9

Group type: COMPARATOR
Intervention: flurbiprofen 200 mg
Number of subjects: 9
Study: 7029149

Group type: EXPERIMENTAL
Intervention: Intrapleural BCG treatment
Number of subjects: 425

Group type: COMPARATOR
Intervention: Intrapleural saline (control)
Number of subjects: 425
Study: 30376369

Group type: EXPERIMENTAL
Intervention: Immediate postpartum levonorgestrel-releasing intrauterine device (LNG-IUD) placement
Number of subjects: 63

Group type: COMPARATOR
Intervention: Interval IUD placement at 6 or more weeks postpartum
Number of subjects: 63
Study: 26800177

Group type: COMPARATOR
Intervention: Implants with anodized surfaces (ANO)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Implants treated by acid (AC)
Number of subjects: 23
Study: 25304922

Group type: EXPERIMENTAL
Intervention: Proactive feeding regimen (PFR), starting with 100 mL/kg/day and gradually increasing to 200 mL/kg/day by day 4.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard feeding regimen, starting with 60 mL/kg/day and gradually increasing to 170 mL/kg/day by day 9.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Proactive feeding regimen (PFR)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard feeding regimen
Number of subjects: 72
Study: 22436957

Group type: EXPERIMENTAL
Intervention: Autologous MSC plus standard-dose CNI
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Autologous MSC plus low-dose CNI
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (anti-IL-2 receptor antibody plus standard-dose CNI)
Number of subjects: 159
Study: 19505968

Group type: EXPERIMENTAL
Intervention: 0.8 ml kg(‐1) of contrast material (350 mgI ml(‐1)) injected with a fixed duration of 10 s (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.8 ml kg(‐1) of contrast material injected with a fixed duration of 14 s (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.7 ml kg(‐1) of contrast material injected with a fixed duration of 10 s (Group C)
Number of subjects: 45
Study: 18467066

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored Health Counseling
Number of subjects: 0
Study: 16437721

Group type: EXPERIMENTAL
Intervention: 90 mL of sodium phosphate (NaP) in a split regimen of two 45 mL doses separated by 12 h
Number of subjects: 80

Group type: COMPARATOR
Intervention: 4 L of polyethylene glycol (PEG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 90 mL of sodium phosphate (NaP)
Number of subjects: 80
Study: 12653815

Group type: EXPERIMENTAL
Intervention: Detoxification with buprenorphine over 3 days
Number of subjects: 123
Study: 10475484

Group type: EXPERIMENTAL
Intervention: Hemopump support during coronary artery bypass operations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemopump support during PTCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemopump in general use
Number of subjects: 0
Study: 8604274

Group type: EXPERIMENTAL
Intervention: Corticotropin (ACTH) 150 U/m2/day for 2 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Prednisone 2 mg/kg/day for 2 weeks
Number of subjects: 29
Study: 1720796

Group type: EXPERIMENTAL
Intervention: Desferal (desferrioxamine) 0.1 mg/ml to 100 mg/ml
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cetirizine 10 mg (H1 antagonist)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Desferal (desferrioxamine)
Number of subjects: 7
Study: 6116097

Group type: EXPERIMENTAL
Intervention: Early return to work after inguinal herniorrhaphy
Number of subjects: 500
Study: 30940423

Group type: EXPERIMENTAL
Intervention: I-HAES group (individual nutritional counseling, group practice of enjoyable physical activity, philosophical workshops)
Number of subjects: 43

Group type: COMPARATOR
Intervention: CTRL group (traditional HAES intervention, lecture-based model)
Number of subjects: 43
Study: 30185448

Group type: EXPERIMENTAL
Intervention: THC (δ‐9‐tetrahydrocannabinol)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27383313

Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate ketogenic diet (VLCKD) with amino acid supplement (whey protein)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Very low restricted-calorie diet (VLCD)
Number of subjects: 25
Study: 24491642

Group type: EXPERIMENTAL
Intervention: Individualized ranibizumab treatment (prior ranibizumab)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Individualized ranibizumab treatment (prior ranibizumab + laser)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment after prior laser
Number of subjects: 240
Study: 21982997

Group type: EXPERIMENTAL
Intervention: Manual bowel decompression (milking)
Number of subjects: 40
Study: 20882651

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 56

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 56

Group type: COMPARATOR
Intervention: Femoral access during PCI
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Radial access during PCI
Number of subjects: 56
Study: 18524013

Group type: EXPERIMENTAL
Intervention: Staged surgical approach with temporary femoral stabilization using an external fixator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grading system for assessment of clinical status
Number of subjects: 0
Study: 15814336

Group type: EXPERIMENTAL
Intervention: THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Two thirds CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: THP-COPE (THP-COP plus etoposide)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: THP-COP
Number of subjects: 486

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: THP-COPE
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Aggressive lymphoma patients
Number of subjects: 486
Study: 14720030

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate 50/250 microg (Seretide/Advair) via Diskus inhaler
Number of subjects: 113

Group type: COMPARATOR
Intervention: budesonide 800 microg (Pulmicort) via Turbuhaler
Number of subjects: 113
Study: 9524980

Group type: EXPERIMENTAL
Intervention: +/- pindolol (30 mg, oral dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7640144

Group type: EXPERIMENTAL
Intervention: Sodium acid pyrophosphate (SAPP) 1.1 g/200 ml
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mannitol 2.264 g/200 ml
Number of subjects: 8

Group type: COMPARATOR
Intervention: Purified water (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucrose 4.08 g/200 ml
Number of subjects: 8
Study: 2707251

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) at doses ranging from 1 to 4 g/day for 13-15 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 19
Study: 73849

Group type: EXPERIMENTAL
Intervention: Levodopa with carbidopa 66 mg/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Levodopa with benserazide 151 mg/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Preference between treatments
Number of subjects: 19

Group type: COMPARATOR
Intervention: Overall comparison of treatments
Number of subjects: 19
Study: 30684563

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28844591

Group type: EXPERIMENTAL
Intervention: Aprepitant 125mg on day 1 and 80mg on days 2 & 3
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 25624436

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 888
Study: 22307212

Group type: EXPERIMENTAL
Intervention: Randomized phase II trials assessing systemic cancer therapies
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Use of formal statistical testing (P values or CIs)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group presence
Number of subjects: 107
Study: 22289537

Group type: EXPERIMENTAL
Intervention: GEM‐AC (gemcitabine adsorbed onto activated carbon particles)
Number of subjects: 8

Group type: COMPARATOR
Intervention: GEM‐Sol (gemcitabine solution)
Number of subjects: 8
Study: 19581197

Group type: EXPERIMENTAL
Intervention: TASK intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 40
Study: 16454930

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 78

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 78
Study: 15003077

Group type: EXPERIMENTAL
Intervention: Paroxetine CR (12.5-37.5 mg/day)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370